Multiple endocrine neoplasia type 1 secondary prevention: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
(Created page with "__NOTOC__ {{Multiple endocrine neoplasia type 1}} {{CMG}}; {{AE}} {{Ammu}} ==Overview== According to the National Caner Institute, surveillance for multiple endocrine neoplasi...")
 
(Mahshid)
 
(7 intermediate revisions by 3 users not shown)
Line 2: Line 2:
{{Multiple endocrine neoplasia type 1}}
{{Multiple endocrine neoplasia type 1}}
{{CMG}}; {{AE}} {{Ammu}}
{{CMG}}; {{AE}} {{Ammu}}
==Overview==
==Overview==
According to the National Caner Institute, surveillance for multiple endocrine neoplasia type 1 by imaging studies such as brain [[MRI]], abdominal [[CT]] and abdominal [[MRI]] are recommended every 3-5 year among patients with [[pituitary tumor]]s and [[pancreatic neuroendocrine tumor]]s respectively. Biochemical tests such as serum [[prolactin]], [[insulin-like growth factor]] 1, fasting total serum [[calcium]], ionized [[calcium]], [[parathyroid hormone]], fasting serum [[gastrin]], [[chromogranin A]], pancreatic polypeptide, [[glucagon]] and vasointestinal polypeptide are recommended every year among patients with [[pituitary tumor]]s,  [[pancreatic neuroendocrine tumor]]s and [[primary hyperparathyroidism]].
According to the National Cancer Institute, surveillance for multiple endocrine neoplasia type-1 by imaging studies such as brain [[MRI]], abdominal [[CT]], and abdominal [[MRI]] is recommended every 3-5 year among patients with [[pituitary tumor]]s and [[pancreatic neuroendocrine tumor]]s respectively. Biochemical tests such as serum [[prolactin]], [[insulin-like growth factor]] 1, fasting total serum [[calcium]], ionized [[calcium]], [[parathyroid hormone]], fasting serum [[gastrin]], [[chromogranin A]], pancreatic polypeptide, [[glucagon]] and vasoactive intestinal polypeptide are recommended every year for patients with [[pituitary tumor]]s,  [[pancreatic neuroendocrine tumor]]s, and [[primary hyperparathyroidism]].


==Surveillance==
==Secondary Prevention==
Surveillance for multiple endocrine neoplasia type 1 may employ a combination of biochemical tests and imaging. Available recommendations are summarized in the following table.<ref name=NCI>{{cite web | title = National Caner Institute Multiple endocrine neoplasia type 1 Surveillance| url =http://www.cancer.gov/types/thyroid/hp/medullary-thyroid-genetics-pdq#link/_775_toc }}</ref>
Surveillance for multiple endocrine neoplasia type 1 may employ a combination of biochemical tests and imaging. Available recommendations are summarized in the following table.<ref name="NCI">{{cite web | title = National Caner Institute Multiple endocrine neoplasia type 1 Surveillance| url =http://www.cancer.gov/types/thyroid/hp/medullary-thyroid-genetics-pdq#link/_775_toc }}</ref><ref name="urlMultiple endocrine neoplasia type 1 - Doherty - 2005 - Journal of Surgical Oncology - Wiley Online Library">{{cite web |url=http://onlinelibrary.wiley.com/doi/10.1002/jso.20181/full |title=Multiple endocrine neoplasia type 1 - Doherty - 2005 - Journal of Surgical Oncology - Wiley Online Library |format= |work= |accessdate=}}</ref><ref name="urlIs Total Parathyroidectomy the Treatment of Choice for Hyper... : Annals of Surgery">{{cite web |url=http://journals.lww.com/annalsofsurgery/Abstract/2007/12000/Is_Total_Parathyroidectomy_the_Treatment_of_Choice.23.aspx |title=Is Total Parathyroidectomy the Treatment of Choice for Hyper... : Annals of Surgery |format= |work= |accessdate=}}</ref>


{|style="border: 0px; font-size: 90%; margin: 3px; width: 700px;" align=center
{| style="border: 0px; font-size: 90%; margin: 3px; width: 700px;" align="center"
! style="background:#4479BA; width: 400px" align=center|{{fontcolor|#FFF| Biochemical Test or Procedure}}
! style="background:#4479BA; width: 400px" align="center" |{{fontcolor|#FFF| Biochemical Test or Procedure}}
! style="background:#4479BA; width: 400px" align=center|{{fontcolor|#FFF| Condition Screened For}}
! style="background:#4479BA; width: 400px" align="center" |{{fontcolor|#FFF| Condition Screened For}}
! style="background:#4479BA; width: 400px" align=center|{{fontcolor|#FFF| Age Screening Initiated (y)}}
! style="background:#4479BA; width: 400px" align="center" |{{fontcolor|#FFF| Age Screening Initiated (y)}}
! style="background:#4479BA; width: 400px" align=center|{{fontcolor|#FFF| Frequency}}
! style="background:#4479BA; width: 400px" align="center" |{{fontcolor|#FFF| Frequency}}
|-
|-
! style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|'''Serum prolactin''' and/or insulin-like growth factor 1'''
! style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align="left" |'''Serum prolactin''' and/or insulin-like growth factor 1
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|[[Pituitary tumor]]s
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align="left" |[[Pituitary tumor]]s
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|'''5'''
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align="left" |'''5'''
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|'''Every 1 year'''
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align="left" |'''Every 1 year'''
|-
|-
! style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|'''Fasting total serum calcium and/or ionized calcium and parathyroid hormone'''  
! style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align="left" |'''Fasting total serum calcium and/or ionized calcium and parathyroid hormone'''  
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|[[Parathyroid]][[tumor]]s and  [[primary hyperparathyroidism]]
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align="left" |[[Parathyroid]][[tumor]]s and  [[primary hyperparathyroidism]]
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|'''8'''
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align="left" |'''8'''
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|'''Every 1 year'''
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align="left" |'''Every 1 year'''
|-
|-
! style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|'''Fasting serum gastrin'''  
! style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align="left" |'''Fasting serum gastrin'''  
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|Duodenopancreatic [[gastrinoma]]  
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align="left" |Duodenopancreatic [[gastrinoma]]  
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|'''20'''
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align="left" |'''20'''
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|'''Every 1 year'''
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align="left" |'''Every 1 year'''
|-
|-
! style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|'''Chromogranin A, pancreatic polypeptide, glucagon, and vasointestinal polypeptide'''  
! style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align="left" |'''Chromogranin A, pancreatic polypeptide, glucagon, and vasointestinal polypeptide'''  
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|[[Pancreatic neuroendocrine tumor]]s
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align="left" |[[Pancreatic neuroendocrine tumor]]s
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|'''<10years'''
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align="left" |'''<10years'''
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|'''Every 1 year'''
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align="left" |'''Every 1 year'''
|-
|-
! style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|'''Fasting glucose and insulin'''  
! style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align="left" |'''Fasting glucose and insulin'''  
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|[[Insulinoma]]
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align="left" |[[Insulinoma]]
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|'''5'''
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align="left" |'''5'''
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|'''Every 1 year'''
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align="left" |'''Every 1 year'''
|-
|-
! style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|'''Brain MRI'''
! style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align="left" |'''Brain MRI'''
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|[[Pituitary tumor]]s
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align="left" |[[Pituitary tumor]]s
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left| '''5'''
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align="left" | '''5'''
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|'''Every 3–5 year based on biochemical results'''
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align="left" |'''Every 3–5 year based on biochemical results'''
|-
|-
! style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|'''Abdominal CT or MRI'''  
! style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align="left" |'''Abdominal CT or MRI'''  
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|[[Pancreatic neuroendocrine tumor]]s  
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align="left" |[[Pancreatic neuroendocrine tumor]]s  
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|'''20'''
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align="left" |'''20'''
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|'''Every 3–5 year based on biochemical results'''
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align="left" |'''Every 3–5 year based on biochemical results'''
|-
|-
! style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|'''Abdominal CT, MRI, or endoscopic US'''  
! style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align="left" |'''Abdominal CT, MRI, or endoscopic US'''  
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|[[Pancreatic neuroendocrine tumor]]s
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align="left" |[[Pancreatic neuroendocrine tumor]]s
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|'''<10'''
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align="left" |'''<10'''
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align=left|'''Every 1 year'''
| style="padding: 0 5px; font-size: 100%; background: #f0f0f0" align="left" |'''Every 1 year'''
|}
|}
==References==
==References==
{{reflist|2}}
{{reflist|2}}


[[Category:Hereditary cancers]]
[[Category:Oncology]]
[[Category:Endocrinology]]
 
{{WS}}
{{WH}}
[[Category:Up-To-Date]]
[[Category:Oncology]]
[[Category:Medicine]]
[[Category:Endocrinology]]
[[Category:Surgery]]

Latest revision as of 02:46, 27 November 2017

Multiple endocrine neoplasia type 1 Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Multiple endocrine neoplasia type 1 from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Multiple endocrine neoplasia type 1 secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Multiple endocrine neoplasia type 1 secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Multiple endocrine neoplasia type 1 secondary prevention

CDC on Multiple endocrine neoplasia type 1 secondary prevention

Multiple endocrine neoplasia type 1 secondary prevention in the news

Blogs on Multiple endocrine neoplasia type 1 secondary prevention

Directions to Hospitals Treating Multiple endocrine neoplasia type 1

Risk calculators and risk factors for Multiple endocrine neoplasia type 1 secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]

Overview

According to the National Cancer Institute, surveillance for multiple endocrine neoplasia type-1 by imaging studies such as brain MRI, abdominal CT, and abdominal MRI is recommended every 3-5 year among patients with pituitary tumors and pancreatic neuroendocrine tumors respectively. Biochemical tests such as serum prolactin, insulin-like growth factor 1, fasting total serum calcium, ionized calcium, parathyroid hormone, fasting serum gastrin, chromogranin A, pancreatic polypeptide, glucagon and vasoactive intestinal polypeptide are recommended every year for patients with pituitary tumors, pancreatic neuroendocrine tumors, and primary hyperparathyroidism.

Secondary Prevention

Surveillance for multiple endocrine neoplasia type 1 may employ a combination of biochemical tests and imaging. Available recommendations are summarized in the following table.[1][2][3]

Biochemical Test or Procedure Condition Screened For Age Screening Initiated (y) Frequency
Serum prolactin and/or insulin-like growth factor 1 Pituitary tumors 5 Every 1 year
Fasting total serum calcium and/or ionized calcium and parathyroid hormone Parathyroidtumors and primary hyperparathyroidism 8 Every 1 year
Fasting serum gastrin Duodenopancreatic gastrinoma 20 Every 1 year
Chromogranin A, pancreatic polypeptide, glucagon, and vasointestinal polypeptide Pancreatic neuroendocrine tumors <10years Every 1 year
Fasting glucose and insulin Insulinoma 5 Every 1 year
Brain MRI Pituitary tumors 5 Every 3–5 year based on biochemical results
Abdominal CT or MRI Pancreatic neuroendocrine tumors 20 Every 3–5 year based on biochemical results
Abdominal CT, MRI, or endoscopic US Pancreatic neuroendocrine tumors <10 Every 1 year

References

  1. ↑ "National Caner Institute Multiple endocrine neoplasia type 1 Surveillance".
  2. ↑ "Multiple endocrine neoplasia type 1 - Doherty - 2005 - Journal of Surgical Oncology - Wiley Online Library".
  3. ↑ "Is Total Parathyroidectomy the Treatment of Choice for Hyper... : Annals of Surgery".

Template:WS Template:WH

Retrieved from "https://www.wikidoc.org/index.php?title=Multiple_endocrine_neoplasia_type_1_secondary_prevention&oldid=1395267"